These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26944826)
1. Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. Lampropoulou-Adamidou K; Tournis S; Triantafyllopoulos IK J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):75-8. PubMed ID: 26944826 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850 [TBL] [Abstract][Full Text] [Related]
3. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT. Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082 [TBL] [Abstract][Full Text] [Related]
4. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Reddy SV; Gupta SK Singapore Med J; 2012 Mar; 53(3):e52-4. PubMed ID: 22434305 [TBL] [Abstract][Full Text] [Related]
5. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report. Bissonnette L; April PM; Dumais R; Boire G; Roux S Bone; 2013 Oct; 56(2):406-9. PubMed ID: 23871749 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review. Hayashi K; Aono M; Shintani K; Kazuki K Anticancer Res; 2014 Mar; 34(3):1245-9. PubMed ID: 24596367 [TBL] [Abstract][Full Text] [Related]
7. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center. Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389 [TBL] [Abstract][Full Text] [Related]
8. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis. Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574 [TBL] [Abstract][Full Text] [Related]
10. [Atypical femoral fractures in bisphosphonate therapy]. Ballaschk A; Kalaitzis N; Röpke M; Piatek S Unfallchirurg; 2015 Jan; 118(1):88-91. PubMed ID: 24352201 [TBL] [Abstract][Full Text] [Related]
11. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078 [TBL] [Abstract][Full Text] [Related]
12. Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer. Kordoni M; Rigakos G; Kim YHM; Kaklamanis L; Nikolatou-Galitis O; Hadjiyassemi L; Labropoulos S; Razis E Anticancer Res; 2018 Nov; 38(11):6439-6444. PubMed ID: 30396969 [TBL] [Abstract][Full Text] [Related]
13. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Adler RA Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529 [TBL] [Abstract][Full Text] [Related]
14. [Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed]. Ing Lorenzinit K; Meier R; Suva D; Dayer P; Desmeules J; Peter R Rev Med Suisse; 2012 Jun; 8(344):1238-42. PubMed ID: 22730621 [TBL] [Abstract][Full Text] [Related]
15. Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease. Lai KH; Chiang CY; Yang RS; Yang KC; Wu CC Acta Clin Belg; 2019 Oct; 74(5):370-374. PubMed ID: 30336748 [No Abstract] [Full Text] [Related]
16. A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid. Ishizuna K; Ota D; Fukuuchi A; Teraoka M; Fujii A; Mori M; Nishi T Breast Cancer; 2015 Jan; 22(1):90-4. PubMed ID: 22009549 [TBL] [Abstract][Full Text] [Related]
17. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215 [TBL] [Abstract][Full Text] [Related]